Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer

SIMPLE SUMMARY: Breast cancer is one of the most common malignant tumors in women. Its incidence rate accounts for 7–10% of all kinds of malignant tumors in the whole body, second only to uterine cancer in women, and has become the main cancer threatening women’s health. Fortunately, it has been proved that combination therapy of immunotherapy with radiotherapy, targeted technology, and even nanotechnology is active and effective in treating breast cancer, which provides a broader way of studying the treatment of breast cancer. Therefore, the purpose of our review is to study the value of immunotherapy in breast cancer treatment. Moreover, because the treatment of triple-negative breast cancer (TNBC) is difficult, we will discuss this in more detail in this article. ABSTRACT: Breast cancer (BC) is a representative malignant tumor that affects women across the world, and it is the main cause of cancer-related deaths in women. Although a large number of treatment methods have been developed for BC in recent years, the results are sometimes unsatisfying. In recent years, treatments of BC have been expanded with immunotherapy. In our article, we list some tumor markers related to immunotherapy for BC. Moreover, we introduce the existing relatively mature immunotherapy and the markers’ pathogenesis are involved. The combination of immunotherapy and other therapies for BC are introduced in detail, including the combination of immunotherapy and chemotherapy, the combined use of immunosuppressants and chemotherapy drugs, immunotherapy and molecular targeted therapy. We summarize the clinical effects of these methods. In addition, this paper also makes a preliminary exploration of the combination of immunotherapy, radiotherapy, and nanotechnology for BC.